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Abstract
Background: Colorectal cancer (CRC) is considered a complex disease, and thus the majority of the genetic susceptibility is
thought to lie in the form of low-penetrance variants following a polygenic model of inheritance. Candidate-gene studies
have so far been one of the basic approaches taken to identify these susceptibility variants. The consistent involvement of
some signaling routes in carcinogenesis provided support for pathway-based studies as a natural strategy to select genes
that could potentially harbour new susceptibility loci.
Methodology/Principal Findings: We selected two main carcinogenesis-related pathways: Wnt and BMP, in order to screen
the implicated genes for new risk variants. We then conducted a case-control association study in 933 CRC cases and 969
controls based on coding and regulatory SNPs. We also included rs4444235 and rs9929218, which did not fulfill our
selection criteria but belonged to two genes in the BMP pathway and had consistently been linked to CRC in previous
studies. Neither allelic, nor genotypic or haplotypic analyses showed any signs of association between the 37 screened
variants and CRC risk. Adjustments for sex and age, and stratified analysis between sporadic and control groups did not
yield any positive results either.
Conclusions/Significance: Despite the relevance of both pathways in the pathogenesis of the disease, and the fact that this
is indeed the first study that considers these pathways as a candidate-gene selection approach, our study does not present
any evidence of the presence of low-penetrance variants for the selected markers in any of the considered genes in our
cohort.
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Introduction
Colorectal cancer (CRC) is one of the main forms of cancer,
being the second most frequent neoplasm in both sexes and one of
the most important morbidity causes in the western world [1]. The
genetic contribution to CRC has been estimated to be around
35% by extensive twin studies [2]. However, highly penetrant
variants, that cause mendelian predisposition syndromes, account
only for, at most, 5% of the disease cases [3]. The remaining
genetic susceptibility is thought to follow a polygenic model, with
an interplay of multiple low-penetrance allelic variants appearing
in high frequency in the general population, and each conferring a
modest effect on disease risk [4,5].
Candidate-gene studies have been one of the most commonly
used tools in the screening for new variants affecting CRC risk.
Gene selection in these studies is mainly based on the functional
implications of a possible association, and thus genes selected have
either been chosen because of the previous presence of other high/
low risk alleles [6], or their participation in a pathway implicated
in the pathogenesis of the disease [7]. Candidate-gene studies can
be performed by either direct approaches, where the variants
genotyped are presumed to be the underlying cause of the disease
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or by indirect approaches, where tag SNPs take advantage of the
linkage disequilibrium properties of the human genome to try and
screen the most of the variability in a given gene.
This latter approach has also allowed, together with the
development of high-throughput technologies, the implementation
of new hypothesis-free approaches (in opposition with hypothesis-
based candidate-gene approaches), covering the majority of the
genome (genome-wide association studies or GWAS). This imple-
mentation has successfully led to the identification of some new
susceptibility loci [8–14], including rs4444235 and rs9929218, that
fall within reach of two genes belonging to the BMP pathway.
Nevertheless, these have been found to predict only a small
proportion of the disease susceptibility, with the remaining yet to
be discovered [15].
We hence aimed to find such susceptibility variants through a
candidate-gene approach screening a selected number of variants
within two cellular pathways that have consistently been linked to
CRC tumorogenesis: the Wnt and the BMP signaling pathways
[16,17].
The Wnt pathway contains genes that have for long been known
to be responsible of some hereditary CRC syndromes, such as APC
and familial adenomatous polyposis [18]. Moreover, somatic
alterations inAPC arefound inalmost 80% of the sporadic colorectal
cancers, and Wnt signaling activation is involved in the best part of
sporadic colorectal carcinomas [19]. On the other hand, the BMP
pathway acts as positive regulator of some of the Wnt proteins [17],
and the tumor suppressive role of this signaling pathway in the
pathogenesis of CRC and other cancers is well established [20,21].
Besides, mutations in two of its genes, SMAD4 and BMPR1A,a r e
responsible for juvenile polyposis syndrome, another hereditary
CRC condition [22]. Considering all this information, we thought it
would be interesting to screen some of the genetic variability within
these pathways for any evidence of new CRC related variants that
could explain at least part of the missing heritability. Our approach
was mainly functional, for only SNPs within exonic or cis-regulatory
sequences (59 and 39 unstranslated regions) were selected to analyse
their relationship with CRC susceptibility.
Results and Discussion
Following our pathway-based candidate-gene selection method,
we performed our study in a total of 45 SNPs that were in either
exonic or regulatory regions, in an overall of 21 genes from both
the Wnt and BMP pathways. Details of SNP features and
association values for the 37 SNPs that successfully passed quality
control criteria are shown on Table 1. None of the screened SNPs
were significantly associated with an altered risk of CRC,
considering odds-ratios and related p values for allelic and
genotypic tests (trend, dominant and recessive). Logistic regression
for age and sex adjustment was performed, although it did not
improve p value results. Haplotype analysis results were consistent
in both Unphased and Haploview, and did not show any signs of
positive associations either for any of the 8 genes for which this
analysis was performed (AXIN1, HDAC9, BMP4, DACT1, CDH3,
CDH1, BTRC, and APC), (Figure S1). Stratification analysis
comparing sporadic and familial cases was also implemented,
but it did not provide any evidence of differences in susceptibilities
between the groups that could be a sign of any specific associations
within either of the groups (Table 2).
Thus, our strategy has not managed to detect any new
susceptibility loci for CRC risk.
Pathway-based expectations have proved to be quite discour-
aging in the literature as well, for strong candidate pathways, such
as DNA-repair ones, surprisingly failed too in identifying any new
risk variants [7,23–24]. In addition to this, most of the genetic
variants that have been found to be associated with disease are
located in intergenic regions, with potential functions that are yet
unknown.
Still, in light of the recent discoveries that followed up the
analysis of genome-wide data, both Wnt and BMP have earned a
renewed fame. The susceptibility locus found on 8q24 (rs6983267)
has been linked to an enhanced Wnt signaling through its
interaction with TCF4 [25,26], and a meta-analysis conducted on
a series of GWAS data succeeded in associating two variants in the
BMP4 and CDH1 gene regions with the disease (rs4444235 and
rs9929218, respectively)[8].
Even though this is actually the first association study that
considers the pathways as a whole for gene selection, some of the
genes included in our analysis (i.e APC, CCND1, CDH1 and TCF7)
had already been screened for risk alleles [6,27–30]. It is quite
remarkable that there has been a growing debate over some of
these loci, specially the p.V1822D variant in APC (rs459552). This
missense change is widely documented in the literature, with some
studies defending it as neutral (this study and others)[31], and
some conferring its minor allele a protective effect [6,28]. Lack of
appropriate study power, resultant from insufficient number of
samples has been a major problem in many of these studies
and thus most of them have not provided very convincing results
[32].
Although our study had over 80% power to detect OR as low
as 1.21 with minor allele frequencies of 0.30 (57% of our SNPs),
and 1.24 for MAFs down to 0.2 (78% of the SNPs), assuming a
log-additive model and a=0.05, we were unable to detect any
positive associations suggesting the presence of any new CRC
susceptibility variants. Nevertheless, it is quite remarkable that,
albeit our failure to replicate the associations for the BMP4 and
CDH1 SNPs, this is the first study that investigates any of the so-
called 10 new GWAS-discovered susceptibility loci in a Southern-
European population.
Despite our negative results, we must consider that we did not
whatsoever comprehensively cover all possible low-penetrance
variants within the selected genes. This is mainly due to the fact
that our strategy was purely functional, selecting the variants that
were a priori good candidates to be directly associated with the
disease. This indeed may constitute a limitation in the study, for
most of the genetic variation within the loci was not investigated.
Thus, we believe further efforts should be made to screen a wider
variety of loci within these pathways, specially considering the
previous positive associations described so far for both Wnt and
BMP-related genes.
Pondering the potential oddsr a t i o so ft h ev a r i a n t sd e s -
cribed so far (1.11, CI 1.08–1.15 and 0.91, CI 0.89–0.94 for
rs4444235 and rs9929218, respectively), we assume larger
cohorts may be required to detect such subtle effects. On the
other hand, when considering candidate-gene approaches, it
would also be useful to meta-analyse previous studies and pull
the information across of them altogether in the search of
evidences of potential new pathways linked to the pathogenesis
of the disease.
Materials and Methods
Study populations
Subjects were 933 CRC patients and 969 controls that belonged
to the EPICOLON project, a prospective, multicentre, popula-
tion-based epidemiology survey studying the incidence and
features of familial and sporadic CRC in the Spanish population
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patients with a de-novo histologically confirmed diagnosis of
colorectal adenocarcinoma and who attended 11 community
hospitals across Spain between November 2006 and December
2007. Patients in whom CRC developed in the context of familial
adenomatous polyposis or inflammatory bowel disease, and cases
where patients or family refused to participate in the study were
excluded. Demographic, clinical and tumour-related characteris-
tics of probands, as well as a detailed family history were obtained
using a pre-established questionnaire, and registered in a single
database. Of these, 592 (63%) were male and 341 (37%) female.
Median age for cases was 73 (range 26–95), whereas mean was
71(SD610.7). Hospital-based controls were recruited together
with cases and were confirmed to have no cancer or prior history
of neoplasm, and no family history of CRC. All controls were
randomly selected and matched with cases for sex and age (65
years) in a 1:1 ratio. Both cases and controls were of European
ancestry and from Spain.
Table 1. Description of the 37 SNPs that passed quality control criteria and their associated p values.
Gene SNP ID SNP type
Amino acid
change Allele
MAF
cases
MAF
controls
GT counts
cases
GT counts
controls p-value OR (95% CI)
ADAR rs2229857 Missense K384R A/G 0.3306 0.3201 99/360/385 88/347/382 0.512 1.05 (0.91–1.22)
APC rs2229992 Synonymous Y486Y C/T 0.3981 0.4125 145/382/317 141/392/284 0.3728 0.94 (0.82–1.08)
APC rs351771 Synonymous A545A C/T 0.3817 0.375 124/397/324 125/416/347 0.7978 1.02 (0.89–1.18)
APC rs41115 Synonymous T1493T C/T 0.3796 0.3761 126/385/328 127/414/347 0.8595 1.00 (0.88–1.16)
APC rs42427 Synonymous G1678G A/G 0.3741 0.3713 124/382/336 116/365/323 0.9252 1.01 (0.88–1.17)
APC rs459552 Missense V1822D A/T 0.2302 0.2134 48/293/504 41/297/550 0.2197 1.11 (0.94–1.30)
APC rs465899 Synonymous P1960P C/T 0.3828 0.3743 126/395/324 125/414/348 0.7107 1.03 (0.90–1.19)
APC rs866006 Synonymous S1756S A/C 0.3775 0.3756 123/370/323 124/401/339 0.925 1.00 (0.87–1.19)
AXIN1 rs1805105 Synonymous D254D C/T 0.3918 0.4096 136/387/318 164/397/324 0.2692 0.93 (0.81–1.07)
AXIN1 rs214250 Synonymous S428S C/T 0.2206 0.2028 32/307/502 34/265/522 0.2138 1.12 (0.94–1.32)
AXIN1 rs214252 Synonymous A609A A/G 0.2207 0.2005 32/305/499 34/258/521 0.1403 1.13 (0.96–1.34)
AXIN1 rs400037 Missense R388Q C/T 0.1826 0.1829 27/244/545 39/234/580 0.8972 1.04 (0.87–1.24)
AXIN2 rs2240308 Missense P50S A/G 0.4502 0.4219 168/423/252 152/442/290 0.1031 1.11 (0.97–1.27)
BMP4 rs17563 Missense V152A C/T 0.4946 0.4855 211/407/220 208/420/233 0.5498 1.07 (0.93–1.23)
BMP4 rs4444235 – – C/T 0.4563 0.4557 168/436/242 196/411/274 0.9343 0.99 (0.86–1.14)*
BTRC rs17767748 Synonymous I229I C/T 0.05516 0.056 3/86/745 4/91/789 0.9324 1.00 (0.74–1.36)
BTRC rs4151060 Missense A543S G/T 0.04793 0.04904 4/73/768 2/83/802 0.6997 0.96 (0.70–1.32)
CCND1 rs603965 Synonymous P241P A/G 0.4969 0.4822 204/406/209 206/430/237 0.4164 1.06 (0.93–1.22)
CDH1 rs1801552 Synonymous A692A C/T 0.3547 0.3781 105/371/343 126/365/325 0.1834 0.92 (0.81–1.07)
CDH1 rs9929218 Intronic – A/G 0.2811 0.2873 65/345/435 83/342/459 0.5486 0.97 (0.83–1.13)*
CDH3 rs1126933 Missense Q563H C/G 0.3828 0.3802 129/382/325 129/361/324 0.8369 1.02 (0.88–1.17)
CDH3 rs17715450 Synonymous R747R A/C 0.3783 0.3959 116/390/316 147/402/330 0.2792 0.93 (0.80–1.07)
CDH3 rs2274239 Synonymous K652K C/T 0.3599 0.3771 108/390/344 126/368/328 0.2863 0.93 (0.81–1.07)
CDH3 rs2296408 Synonymous T271T G/T 0.3698 0.3724 107/394/321 130/388/352 0.8768 1.00 (0.87–1.15)
CDH3 rs2296409 Synonymous T240T C/T 0.3585 0.3643 106/391/344 130/387/371 0.7962 0.98 (0.85–1.13)
CDH3 rs8049247 Synonymous I204I A/C 0.1665 0.1682 21/238/582 22/249/600 0.8683 0.97 (0.81–1.17)
DACT1 rs17832998 Missense A464V C/T 0.3468 0.3448 111/362/369 116/381/392 0.9293 1.01 (0.88–1.17)
DACT1 rs863091 Synonymous V378V C/T 0.2047 0.2033 30/283/525 41/249/524 0.932 1.01 (0.85–1.19)
HDAC9 rs1178127 Missense P621P A/G 0.21 0.2203 37/273/516 41/300/526 0.4737 0.94 (0.80–1.12)
HDAC9 rs34096894 Synonymous L152L C/T 0.01953 0.01351 0/33/812 1/22/865 0.2075 1.33 (0.78–2.27)
NLK rs3182380 Synonymous I498I C/T 0.05142 0.05535 2/83/761 3/85/734 0.4686 0.92 (0.68–1.24)
PPARD rs2076167 Synonymous N163N A/G 0.2956 0.294 72/355/417 78/328/417 0.9891 1.00 (0.86–1.16)
SMURF1 rs219797 Synonymous S166S C/G 0.4452 0.4712 160/428/252 210/415/261 0.1591 0.90 (0.78–1.03)
TCF7 rs30489 Missense G256R C/T 0.07683 0.07937 6/118/722 6/128/748 0.7655 0.97 (0.75–1.25)
TLE1 rs2228173 Synonymous E118E A/G 0.1183 0.1172 11/178/656 6/196/685 0.992 1.02 (0.82–1.26)
WIF1 rs7301320 Synonymous A73A C/T 0.2237 0.2219 48/265/494 47/281/517 0.9768 1.00 (0.84–1.18)
WNT2B rs910697 Synonymous Q390Q A/G 0.4218 0.4301 154/404/286 172/419/296 0.5463 0.95 (0.83–1.09)
Minor allele is depicted in bold.
MAF. Minor Allele Frequency; OR 95% CI. Odds Ratio and 95% Confidence Interval. GT counts. Genotype counts.
*Described OR (95%CI) for rs4444235 and rs9929218 were 1.11 (1.08–1.15) and 0.91 (0.89–0.94), respectively, as taken from Houlston et al.. Nat Genet 2008.
doi:10.1371/journal.pone.0012673.t001
Wnt-BMP Pathways in CRC Risk
PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e12673Ethics statement
The study was approved by the ‘‘Comite ´E ´tico de Investigacio ´n
Clı ´nica de Galicia’’, and each of the institutional review boards of
the hospitals where samples were collected (‘‘Ethics Committee of
the Hospital Clı ´nic-Barcelona’’, ‘‘Ethics Committee of the
Hospital del Mar-Barcelona’’, ‘‘Ethics Committee of the Hospital
German Trias i Pujol-Barcelona’’, ‘‘Ethics Committee of the
Hospital Sant Pau-Barcelona,’’ ‘‘Ethics Committee of the Hospital
Universitari Arnau de Vilanova-Lleida’’, ‘‘Ethics Committee of
the Hospital General-Alicante’’, ‘‘Ethics Committee of the
Hospital de Donosti’’, ‘‘Ethics Committee of the Hospital General
de Asturias-Oviedo’’, ‘‘Ethics Committee of the Hospital Clinico-
Zaragoza’’, ‘‘Ethics Committee of the Hospital de Calahorra-La
Rioja’’, ‘‘Ethics Committee of the Hospital Meixoeiro-Vigo’’). All
samples were obtained with written informed consent reviewed by
the ethical board of the corresponding hospital.
DNA extraction
DNA was obtained from frozen peripheral blood; extraction
was performed in a CHEMAGEN robot (Chemagen Biopolymer-
Table 2. Association values for stratified analysis in familial and sporadic CRC groups.
Familial vs control Sporadic vs control Familial vs sporadic
ADAR rs2229857 0.08586 1.28 (0.97–1.68) 0.8662 1.01 (0.87–1.18) 0.1011 1.26 (0.95–1.67)
APC rs2229992 0.6564 1.06 (0.81–1.39) 0.2732 0.92 (0.80–1.07) 0.3214 1.15 (0.87–1.51)
APC rs351771 0.3266 1.15 (0.87–1.50) 0.8956 1.01 (0.87–1.17) 0.3659 1.14 (0.86–1.49)
APC rs41115 0.4254 1.12 (0.85–1.47) 0.9802 1.00 (0.86–1.15) 0.4306 1.12 (0.85–1.47)
APC rs42427 0.3978 1.13 (0.86–1.48) 0.9322 0.99 (0.86–1.15) 0.3825 1.13 (0.86–1.49)
APC rs459552 0.05147 1.35 (1.00–1.83) 0.4821 1.06 (0.90–1.26) 0.1313 1.27 (0.93–1.72)
APC rs465899 0.3161 1.15 (0.88–1.51) 0.8003 1.02 (0.88–1.18) 0.3885 1.13 (0.86–1.49)
APC rs866006 0.3634 1.14 (0.86–1.49) 0.8589 0.99 (0.85–1.14) 0.3256 1.15 (0.87–1.52)
AXIN1 rs1805105 0.0674 0.77 (0.58–1.02) 0.5492 0.96 (0.83–1.10) 0.1524 0.81 (0.61–1.08)
AXIN1 rs214250 0.5041 1.12 (0.81–1.55) 0.2312 1.11 (0.93–1.32) 0.9975 1.00 (0.72–1.39)
AXIN1 rs214252 0.4511 1.13 (0.82–1.57) 0.1736 1.13 (0.95–1.34) 0.9984 1.00 (0.72–1.39)
AXIN1 rs400037 0.1971 1.25 (0.89–1.74) 0.6545 0.96 (0.80–1.15) 0.1447 1.29 (0.92–1.81)
AXIN2 rs2240308 0.7901 1.04 (0.78–1.36) 0.0733 1.14 (0.99–1.31) 0.5069 0.91 (0.69–1.20)
BMP4 rs17563 0.1037 1.25(0.95–1.64) 0.9434 1.01 (0.87–1.16) 0.1119 1.25 (0.95–1.64)
BMP4 rs4444235 0.2311 0.85 (0.65–1.11) 0.6689 1.03 (0.90–1.19) 0.1486 0.82 (0.62–1.08)
BTRC rs17767748 0.7285 1.10 (0.63–1.93) 0.813 0.96 (0.71–1.31) 0.6361 1.15 (0.65–2.03)
BTRC rs4151060 0.1176 1.52 (0.90–2.57) 0.4741 0.89 (0.64–1.24) 0.04729 1.72 (1.00–2.96)
CCND1 rs603965 0.335 0.87 (0.66–1.15) 0.2045 1.10 (0.95–1.26) 0.1203 0.80 (0.61–1.06)
CDH1 rs1801552 0.6563 1.07 (0.80–1.41) 0.08919 0.88 (0.76–1.02) 0.1812 1.21 (0.91–1.61)
CDH1 rs9929218 0.8686 0.98 (0.73–1.31) 0.6861 0.97 (0.83–1.13) 0.926 1.01 (0.75–1.37)
CDH3 rs1126933 0.1283 1.23 (0.94–1.62) 0.7438 0.98 (0.84–1.13) 0.09059 1.27 (0.96–1.67
CDH3 rs17715450 0.2767 0.86 (0.65–1.13) 0.4126 0.94 (0.82–1.09) 0.5064 0.91 (0.68–1.21)
CDH3 rs2274239 0.1972 0.83 (0.63–1.10) 0.4589 0.95 (0.82–1.10) 0.3649 0.88 (0.66–1.17)
CDH3 rs2296408 0.4447 0.90 (0.68–1.19) 0.9386 1.01 (0.87–1.16) 0.4216 0.89 (0.67–1.18)
CDH3 rs2296409 0.1256 0.80 (0.60–1.07) 0.9158 1.01 (0.87–1.17) 0.1138 0.79 (0.59–1.06)
CDH3 rs8049247 0.9636 1.01 (0.71–1.44) 0.867 0.98 (0.82–1.19) 0.9021 1.02 (0.71–1.47)
DACT1 rs17832998 0.9185 0.99 (0.74–1.31) 0.8619 1.01 (0.88–1.17) 0.8392 0.97 (0.73–1.29)
DACT1 rs863091 0.5683 0.90 (0.64–1.28) 0.7737 1.03 (0.86–1.22) 0.4595 0.88 (0.62–1.24)
Gene SNP ID p-value OR (CI 95%) p-value OR (CI 95%) p-value OR (CI 95%)
HDAC9 rs1178127 0.8693 1.03 (0.74–1.42) 0.3847 0.93 (0.78–1.10) 0.5511 1.11 (0.80–1.54)
HDAC9 rs34096894 0.8555 0.89 (0.27–2.99) 0.1093 1.55 (0.90–2.67) 0.3638 0.58 (0.18–1.91)
NLK rs3182380 0.4747 0.79 (0.42–1.50) 0.7387 0.95 (0.69–1.30) 0.5917 0.84 (0.44–1.60
PPARD rs2076167 0.1051 0.77 (0.57–1.06) 0.5291 1.05 (0.90–1.23) 0.06342 0.74 (0.55–1.02)
SMURF1 rs219797 0.9123 0.99 (0.75–1.29) 0.09224 0.89 (0.77–1.02) 0.4764 1.10 (0.84–1.45)
TCF7 rs30489 0.1722 1.36 (0.87–2.11) 0.4351 0.90 (0.69–1.17) 0.07095 1.51 (0.96–2.38)
TLE rs2228173 0.4715 1.16 (0.78–1.71) 0.8995 0.99 (0.79–1.23) 0.4626 1.16 (0.78–1.73)
WIF1 rs7301320 0.2681 1.20 (0.87–1.64) 0.8226 0.98 (0.83–1.16) 0.2418 1.21 (0.88–1.67)
WNT2B rs910697 0.4228 0.90 (0.68–1.17) 0.7713 0.98 (0.85–1.13) 0.5418 0.92 (0.70–1.21)
MAF. Minor Allele Frequency; OR 95% CI. Odds Ratio and 95% Confidence Interval.
doi:10.1371/journal.pone.0012673.t002
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Gene Name Function
pathway/genes modulated
by BMP signalling SNPs selected
ADAR, Adenosine deaminase,
RNA- specific
Converts multiple adenosines to inosines
and creates I/U mismatched base pairs in
double-helical RNA
Wnt signalling
36 rs2229857
APC, Adenomatous Polyposis Coli B-catenin degradation Wnt signalling
36 rs2229992,rs351771,rs4115,
rs42427rs459552,rs465899,rs86006
AXIN1, Axin 1 B-catenin regulation Wnt signalling
36 rs1048786,rs1805105,rs214250,
rs214252,rs400037,rs419949
BTRC, Beta-transducin repeat
containing
B-catenin ubiquitination Wnt signalling
36 rs17767748,rs415060
CCND1, Cyclin D1 Cell cycle control Wnt signalling
36 rs603965
CSNK1A1, Casein kinase 1, alpha 1 B-catenin fosforilation Wnt signalling
36 NA
CSNK2A1, Casein kinase 2, alpha 1 B-catenin fosforilation Wnt signalling
36 NA
CTBP1, C-terminal binding protein 1 Transcriptional repressor in cellular
proliferation
Wnt signalling
36 NA
CTNNB1, Catenin (cadherin-associated
protein), beta 1
Cell adhesion and signal transduction Wnt signalling
36 NA
EIF4E, Eukaryotic translation initiation
factor 4E
Translation initiation factor Wnt signalling
36 NA
ELAC1, ElaC homolog 1 (E. coli) Zinc phosphodiesterase Wnt signalling
36 NA
FRAT1, Frequently rearranged in advanced
T-cell lymphomas
B-catenin stabilization Wnt signalling
36 NA
FZD1, Frizzled homolog 1 (Drosophila) Receptor for Wnt proteins Wnt signalling
36 NA
GSK3B, Glycogen synthase kinase 3
beta
B-catenin fosforilation Wnt signalling
36 rs34002644
HDAC9, Histone deacetylase 9 Transcriptional regulation, cell cycle Wnt signalling
36 rs1178127,rs34096894
HNF4A, Hepatocyte nuclear factor 4,
alpha
Transcriptionally controlled transcription
factor
Wnt signalling
36 rs35078168
MAP3K7, Mitogen-activated protein kinase
kinase kinase 7
Signaling transduction induced by BMP Wnt signalling
36 NA
MYC, v-myc myelocytomatosis viral
oncogene homolog (avian)
Regulation of gene transcription Wnt signalling
36 NA
NLK, Nemo-like kinase Negatively regulation wnt pathway Wnt signalling
36 rs3182380
PPARD, Peroxisome proliferator-
activated receptor delta
Ligand-activated transcription factor. Wnt signalling
36 rs2076167
PPP2R4, Protein phosphatase 2A activator,
regulatory subunit 4
Folding of proteins Wnt signalling
36 NA
TLE1, Transducin-like enhancer of
split 1 (E(sp1) homolog, Drosophila)
Transcriptional corepressor Wnt signalling
36 rs2228173,rs8782
WIF1, Wnt inhibitory factor 1 Inhibition of the WNT activities Wnt signalling
36 rs1026024,rs7301320
WNT1, Wingless-type MMTV integration
site family, member 1
Ligand for members of the frizzled family Wnt signalling
36 NA
BMP4, Bone morphogenetic protein 4 Induces cartilage and bone formation. BMP signalling
17 rs17563
BMPR1B, Bone morphogenetic protein
receptor, type IB
Transmembrane serine/threonine BMP signalling
17 NA
SMAD1, SMAD family member 1 Signal transduction BMP signalling
17 NA
SMAD4, SMAD family member 4 Signal transduction BMP signalling
17 rs75667697
SMAD5, SMAD family member 5 Signal transduction BMP signalling
17 NA
SMURF1, SMAD specific E3 ubiquitin
protein ligase 1
Ubiquitination and degradation of SMAD
proteins
BMP signalling
17 rs219797
AXIN2, Axin 2 B-catenin regulation Wnt signalling, BMP induced
genes
34
rs2240308
CDH1, Cadherin 1, type 1, E-cadherin B-catenin regulation Wnt signalling, BMP induced
genes
34
rs1801552
CDH3, Cadherin 3, type 1, P-cadherin
(placental)
B-catenin regulation Wnt signalling, BMP induced
genes
34
rs1126933,rs17715450,rs2274239,
rs2296408,rs2296409,rs8049247
DAB2, Disabled homolog 2,
mitogen-responsive phosphoprotein
B-catenin regulation Wnt signalling, BMP induced
genes
34
NA
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manufacturer’s instructions, at the Galician Public Fundation of
Genomic Medicine in Santiago de Compostela. Cases and
controls were extracted in mixed batches to avoid any kind of
bias.
Candidate-gene selection
Both Wnt and BMP pathways were initially selected after the
findings of Nishanian et al. [34], who demonstrated the interaction
between these two pathways. Both pathways were thoroughly
investigated through the Cancer Genome Anatomy Project site
[35], but we failed to find any information regarding the BMP
pathway in either this or other web browsers. For that reason, Wnt
genes were selected by browsing the pathway through Biocarta
[36], whereas BMP genes had to be strictly selected from previous
literature [17,34]. Forty-one genes were finally selected to be
included in the analysis.
SNP selection and genotyping
SNP selection criteria only considered functional markers
with minor allele frequencies above 0.05 and at least two
independent validation criteria as established in dbSNP [37].
This included all exonic variants selected with Pupasuite [38]
and gene-regulatory regions in cis (59or 39 UTR ends), as
defined by the FESD web browser [39]. 59UTR variants were
only included when they complied to the abovementioned
criteria and were presumed to be in the potential binding site of
a known transctiptional binding factor. 39 UTR variants were
included because of their potential relationship with miRNA
binding regions [40]. Because some of the selected genes had no
SNPs of such these kinds in any of the three browsers at the time
of SNP selection, they ultimately had to be dropped out of the
study. Finally, 43 SNPs were chosen within 21 genes to be
screened as potential direct modifiers of CRC susceptibility
(Table 3).
rs4444235 and rs9929218 are two variants lying in the near-by
and intronic regions of BMP4 and CDH1, respectively, that have
been recently reported to be associated with the disease [8].
Considering that the SNPs that we had chosen within these two
genes were not good taggers for these two variants (r-squared
values were 0.6 for the SNPs in BMP4, and 0.02 for those in
CHD1) (Figure 1), we decided to include them in our study as well,
although they did not fulfill our selection criteria, making the total
number of interrogated SNPs rise to 45.
Genotyping was performed with the MassARRAY (Sequenom
Inc., San Diego, USA) technology at the Santiago de Compostela
node of the Spanish Genotyping Center. Calling of genotypes was
done with Sequenom Typer v4.0 software using all the data from
the study simultaneously.
Statistical analyses
Quality control was performed, first by excluding both SNPs
and samples with genotype success rates below 95%, with the
help of the Genotyping Data Filter (GDF) [41]. Genotypic
distributions for all SNPs in controls were consistent with Hardy-
Weinberg equilibrium as assessed using a X
2 test (1
df). All p-
values obtained were $0.05, thereby excluding the possibility of
genotyping artifacts (data not shown). Population stratification
was assessed with Structure v2.2 [42]. Briefly, the posibility of
different scenarios was tested assuming a different number of
underlying populations (k ranging from 1 to 4), allowing for a
large number of iterations (25 K in the burn-in period followed
by 500 K repetitions). The mean log likelihood was estimated for
the data for a given k (referred to as L(K)) in each run. We as well
performed multiple runs for each value of k computing the
overall mean L(K) and its standard deviation. All results seemed
to be concordant with the original assumption of a single existing
population. Moreover, additional procedures for better con-
founding variable visualization were undertaken by means of a
Principal Component Analysis (PCA) using the EIGENSOFT
tool smartpca [43], although number of markers was very low. No
differences were found of population stratification between cases
and controls for either STRUCTURE or the first 10 components
of the PCA analysis (Figure S2). After quality control 1746
samples (854 cases and 892 controls) and 37 SNPs remained for
further analyses.
Gene Name Function
pathway/genes modulated
by BMP signalling SNPs selected
DACT1, Dapper antagonist of beta-catenin,
homolog 1 (Xenopus laevis)
Disheveled inhibitor Wnt signalling, BMP induced
genes
34
rs17832998,rs698025,rs863091
KIFAP3, Kinesin-associated protein 3 Interacts with apc Wnt signalling, BMP induced
genes
34
NA
LEF1, Lymphoid enhancer-binding factor 1 Transcriptional activator of Wnt signaling Wnt signalling, BMP induced
genes
34
NA
TCF7, Transcription factor 7
(T-cell specific, HMG-box)
transcriptional repressor of CTNNB1 Wnt signalling, BMP induced
genes
34
rs30489
WNT2B, Wingless-type MMTV integration
site family, member 2B
Wnt ligand Wnt signalling, BMP induced
genes
34
rs910697
WNT5A, Wingless-type MMTV integration
site family, member 5A
Wnt ligand Wnt signalling, BMP induced
genes
34
NA
WNT5B, Wingless-type MMTV integration
site family, member 5B
Wnt ligand Wnt signalling, BMP induced
genes
34
NA
Genes finally screened are depicted in bold.
NA denotes not available SNPs for a given gene considering our selection criteria. rs4444235 and rs9929218 are not shown, for they were included because of their
previous associations and not because they fulfilled our functional criteria.
doi:10.1371/journal.pone.0012673.t003
Table 3. Cont.
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PLoS ONE | www.plosone.org 7 September 2010 | Volume 5 | Issue 9 | e12673Association tests were performed by chi-squared tests for every
single SNP and haplotypes where possible with both Haploview
v4.0 [44] and Unphased [45]. In short, LD patterns across genes for
which more than one SNP was genotyped were checked in
Haploview and tested for association using Unphased (to check in
any of the haplotypes was associated) and Haploview (to see which
of the haplotypes was associated). Genotypic association tests,
logistic regression analysis for sex and age adjustment, and stratified
analysis between sporadic and familial groups were estimated with
PLINK v1.03 [46]. OR and 95% confidence intervals were
calculated for each statistic, and to address the issue of multiple-
testing, permutation tests and the Bonferroni correction were used.
Study power was estimated with CATS software [47].
Supporting Information
Figure S1 Haplotype structure and analysis for the 8 genes for
which more than one SNP was genotyped. The table shows
association values for each SNP generated by Haploview.
Found at: doi:10.1371/journal.pone.0012673.s001 (3.40 MB TIF)
Figure S2 Principal component analysis plot for the first vs.
second component, comparing our case and control populations.
Found at: doi:10.1371/journal.pone.0012673.s002 (0.96 MB TIF)
Note S1
Found at: doi:10.1371/journal.pone.0012673.s003 (0.03 MB
DOC)
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